Latest Breaking News On - Roger crystal - Page 7 : comparemela.com

Opiant Pharmaceuticals (OPNT) Granted US Patent With Claims Covering OPNT003

Opiant Pharmaceuticals (OPNT) Granted US Patent With Claims Covering OPNT003
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ben atkinsTrademark officeNeurelis incExchange commission onDrug administrationAegis therapeuticsOpiant pharmaceuticals incOpiant pharmaceuticalsOpioid overdoseNapproved drug productsTherapeutic equivalence evaluationsOrange bookRoger crystalChief executive officerNew drug applicationFast track designation

Opiant Pharmaceuticals (OPNT) Expands Collaboration with Antar Pharma to Manufacture Unidose Nasal Spray for OPNT003

Opiant Pharmaceuticals (OPNT) Expands Collaboration with Antar Pharma to Manufacture Unidose Nasal Spray for OPNT003
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Aptar pharmaDrug administrationOpiant pharmaceuticals incWall streetRoger crystalChief executive officerNew drug applicationFast track designation

Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene

08.06.2022 - Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003SANTA MONICA, Calif., June 08, 2022 (GLOBE NEWSWIRE) - Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: .

Ben atkinsExchange commissionDrug administrationOpiant pharmaceuticals incRoger crystalChief executive officerNew drug applicationFast track designationOpiant pharmaceuticalsInvestor inquiries

Opiant Pharmaceuticals, Inc (OPNT) CEO Dr Roger Crystal on Q1 2022 Results - Earnings Call Transcript

Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q1 2022 Results Conference Call May 10, 2022 04:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor.

United statesLeland lelgershellCarl edward byrnes northlandPhil skolnickLeland gershellBen atkinsMark ellisonMatt ruthDavid bautzBrandon folkesDavid otooleCompany participantsNational institute on drug abuseBiomedical advanced researchNational institutes of healthEmergent biosolutions inc

Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

10.05.2022 - SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) - Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the .

Ben atkinsDavid otooleCenters for diseaseHuman servicesBiomedical advanced researchEmergent biosolutions incOpiant pharmaceuticals incDevelopment authorityExchange commissionDepartment of healthCorporate communicationsOffice of theEmergent biosolutionsNew drug applicationDisease controlAlcohol use disorder